Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Percy Ivy

Showing results (21-30 of 143) with videos related to

Pageof 15
Sort By:
The Lancet. Oncology|August 16, 2021
Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participantsMorgan A Casal, S Percy Ivy, Jan H Beumer, et al.
Cancer Chemotherapy and Pharmacology|November 24, 2016
Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignanciesCharles A Kunos, Edward Chu, Jan H Beumer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2016
Measuring Toxicity in Phase I Clinical Trials--LetterDavid M Hyman, Anne Eaton, S Percy Ivy, et al.
Frontiers in Oncology|November 5, 2019
Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal CancersCharles A Kunos, Stephen J Andrews, Kathleen N Moore, et al.
Expert Opinion on Investigational Drugs|February 23, 2016
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancerS Percy Ivy, Joyce F Liu, Jung-Min Lee, et al.
Melanoma Research|February 16, 2013
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011Jason J Luke, Lawrence V Rubinstein, Gary L Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanibKostandinos Sideras, Michael E Menefee, Jill K Burton, et al.
Leukemia & Lymphoma|July 16, 2005
The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology GroupDouglas P Olson, Barbara J Taylor, Mei La, et al.
Cancer Letters|February 2, 2024
Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patientsMorgan A Butrovich, Jiyue Qin, Xiaonan Xue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Design issues of randomized phase II trials and a proposal for phase II screening trialsLawrence V Rubinstein, Edward L Korn, Boris Freidlin, et al.
Pageof 15

Showing results (21-30 of 143) with videos related to

Sort By:
Pageof 15
The Lancet. Oncology|August 16, 2021
Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participantsMorgan A Casal, S Percy Ivy, Jan H Beumer, et al.
Cancer Chemotherapy and Pharmacology|November 24, 2016
Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignanciesCharles A Kunos, Edward Chu, Jan H Beumer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2016
Measuring Toxicity in Phase I Clinical Trials--LetterDavid M Hyman, Anne Eaton, S Percy Ivy, et al.
Frontiers in Oncology|November 5, 2019
Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal CancersCharles A Kunos, Stephen J Andrews, Kathleen N Moore, et al.
Expert Opinion on Investigational Drugs|February 23, 2016
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancerS Percy Ivy, Joyce F Liu, Jung-Min Lee, et al.
Melanoma Research|February 16, 2013
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011Jason J Luke, Lawrence V Rubinstein, Gary L Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanibKostandinos Sideras, Michael E Menefee, Jill K Burton, et al.
Leukemia & Lymphoma|July 16, 2005
The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology GroupDouglas P Olson, Barbara J Taylor, Mei La, et al.
Cancer Letters|February 2, 2024
Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patientsMorgan A Butrovich, Jiyue Qin, Xiaonan Xue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Design issues of randomized phase II trials and a proposal for phase II screening trialsLawrence V Rubinstein, Edward L Korn, Boris Freidlin, et al.
Pageof 15